LAS VEGAS, March 17, 2015 /PRNewswire/ — The International Society for CNS Drug Development (ISCDD) announced today thatAntony Loebel, M.D., Executive Vice President and Chief Medical Officer at Sunovion is the recipient of the 2015 ISCDD Award for Leadership at its 13th Annual Meeting.
The 2015 ISCDD Award was presented to Dr. Loebel by Dr. George Garibaldi, the Chairman of the ISCDD Executive Committee, and Dr. Amir Kalali, Executive Secretary, ISCDD.
Dr. Loebel was nominated based on his track record of leading the successful development of new treatments for patients with brain disorders, as well as for his innovative approaches in research and development.
"Dr. Loebel's contributions to the field of CNS drug development are remarkable," says Dr. Garibaldi. "He is driven by his passion for patients and has undertaken many innovative research initiatives aimed at improving the standard of care."
In an interview following the Awards Ceremony, Dr. Loebel discussed the factors leading to his success developing new treatments. He emphasized the strong support for neuroscience research at Sunovion, the contributions of colleagues, partners, investigators, and patients, as well as learning from clinical experience, and the utilization of innovative approaches.
"I am honored to be recognized with this award, which brings attention to the need for improved therapies for patients," said Dr. Loebel.
Founded in 2002 as a leadership forum for central nervous system drug development, the International Society for CNS Drug Development (ISCDD) is a non-profit, independent society focused on improving CNS drug development, through collaboration among stakeholders including academia, industry and government.
For more information, please contact:
Erica Moore
ISCDD Secretariat
702-992-0784
Email